DE1292303T1 - Eine stabile pharmazeutische formulierung die torsemid modifikation ii enthält - Google Patents
Eine stabile pharmazeutische formulierung die torsemid modifikation ii enthältInfo
- Publication number
- DE1292303T1 DE1292303T1 DE1292303T DE01911078T DE1292303T1 DE 1292303 T1 DE1292303 T1 DE 1292303T1 DE 1292303 T DE1292303 T DE 1292303T DE 01911078 T DE01911078 T DE 01911078T DE 1292303 T1 DE1292303 T1 DE 1292303T1
- Authority
- DE
- Germany
- Prior art keywords
- pharmaceutical formulation
- stable pharmaceutical
- formulation according
- torsemide modification
- modification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012986 modification Methods 0.000 title claims abstract 18
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 18
- 230000004048 modification Effects 0.000 title claims abstract 17
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 claims abstract 16
- 229960005461 torasemide Drugs 0.000 claims abstract 16
- 238000009472 formulation Methods 0.000 claims abstract 4
- 239000000203 mixture Substances 0.000 claims abstract 4
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract 2
- 238000004090 dissolution Methods 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 229960004977 anhydrous lactose Drugs 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18328800P | 2000-02-17 | 2000-02-17 | |
| US09/789,424 US6482417B2 (en) | 2000-02-17 | 2001-02-21 | Stable pharmaceutical formulation comprising torsemide modification II |
| PCT/US2001/005577 WO2002067935A1 (en) | 2000-02-17 | 2001-02-21 | A stable pharmaceutical formulation comprising torsemide modification ii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1292303T1 true DE1292303T1 (de) | 2003-09-18 |
Family
ID=27359046
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE1292303T Pending DE1292303T1 (de) | 2000-02-17 | 2001-02-21 | Eine stabile pharmazeutische formulierung die torsemid modifikation ii enthält |
| DE60103276T Expired - Fee Related DE60103276T2 (de) | 2000-02-17 | 2001-02-21 | Eine stabile pharmazeutische formulierung die torsemid modifikation ii enthält |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60103276T Expired - Fee Related DE60103276T2 (de) | 2000-02-17 | 2001-02-21 | Eine stabile pharmazeutische formulierung die torsemid modifikation ii enthält |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6482417B2 (enExample) |
| EP (1) | EP1292303B1 (enExample) |
| JP (1) | JP2004522780A (enExample) |
| CN (1) | CN1505512A (enExample) |
| AT (1) | ATE266404T1 (enExample) |
| CA (1) | CA2410802A1 (enExample) |
| DE (2) | DE1292303T1 (enExample) |
| DK (1) | DK1292303T3 (enExample) |
| ES (1) | ES2193007T3 (enExample) |
| HR (1) | HRP20030762A2 (enExample) |
| HU (1) | HUP0600143A2 (enExample) |
| IL (1) | IL157539A0 (enExample) |
| IS (1) | IS6919A (enExample) |
| MX (1) | MXPA03007908A (enExample) |
| NO (1) | NO20033699L (enExample) |
| PT (1) | PT1292303E (enExample) |
| SI (1) | SI1292303T1 (enExample) |
| SK (1) | SK11632003A3 (enExample) |
| TR (1) | TR200401462T4 (enExample) |
| WO (1) | WO2002067935A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10013289A1 (de) * | 2000-03-17 | 2001-09-20 | Knoll Ag | Torasemid enthaltende pharmazeutische Zubereitungen |
| US20030022921A1 (en) * | 2001-02-21 | 2003-01-30 | Minutza Leibovici | Stable pharmaceutical formulation comprising torsemide modification II |
| ITMI20020639A1 (it) * | 2002-03-27 | 2003-09-29 | Cosma S P A | Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea |
| WO2005044187A2 (en) * | 2003-10-28 | 2005-05-19 | Glaxo Group Limited | Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same |
| ES2244324B1 (es) * | 2004-03-25 | 2006-11-16 | Ferrer Internacional, S.A. | Composiciones diureticas de liberacion prolongada. |
| CN100421662C (zh) * | 2005-11-08 | 2008-10-01 | 周卓和 | 托拉塞米分散片及其制备方法和应用 |
| CN100372534C (zh) * | 2006-04-20 | 2008-03-05 | 南京海辰药业有限公司 | 托拉塞米冻干制剂及制备方法 |
| US20080213362A1 (en) * | 2007-02-02 | 2008-09-04 | Lawrence Solomon | Compositions and methods using torsemide |
| CN106038500A (zh) * | 2016-05-26 | 2016-10-26 | 南京正科医药股份有限公司 | 一种托拉塞米片 |
| GR1010905B (el) * | 2024-04-15 | 2025-03-10 | Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια, | Δισκιο που περιεχει τορασεμιδη |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1477664A (en) | 1974-04-17 | 1977-06-22 | Christiaens Sa A | Pyridine derivatives |
| DE3529529A1 (de) | 1985-08-17 | 1987-02-19 | Boehringer Mannheim Gmbh | Verfahren zur herstellung einer stabilen modifikation von torasemid |
| CA2213700C (en) * | 1995-02-28 | 2002-04-02 | Hoechst Marion Roussel, Inc. | Pharmaceutical composition for piperidinoalkanol compounds |
| US5914336A (en) * | 1998-06-02 | 1999-06-22 | Boehringer Mannheim Gmbh | Method of controlling the serum solubility of orally administered torasemide and composition relating thereto |
| HRP20020120A2 (en) * | 1999-08-11 | 2003-10-31 | Teva Pharma | Torsemide polymorphs |
-
2001
- 2001-02-21 SK SK1163-2003A patent/SK11632003A3/sk not_active Application Discontinuation
- 2001-02-21 JP JP2002567302A patent/JP2004522780A/ja not_active Withdrawn
- 2001-02-21 IL IL15753901A patent/IL157539A0/xx unknown
- 2001-02-21 HR HR20030762A patent/HRP20030762A2/xx not_active Application Discontinuation
- 2001-02-21 EP EP01911078A patent/EP1292303B1/en not_active Revoked
- 2001-02-21 ES ES01911078T patent/ES2193007T3/es not_active Expired - Lifetime
- 2001-02-21 MX MXPA03007908A patent/MXPA03007908A/es not_active Application Discontinuation
- 2001-02-21 HU HU0600143A patent/HUP0600143A2/hu unknown
- 2001-02-21 SI SI200130132T patent/SI1292303T1/xx unknown
- 2001-02-21 DK DK01911078T patent/DK1292303T3/da active
- 2001-02-21 CA CA002410802A patent/CA2410802A1/en not_active Abandoned
- 2001-02-21 PT PT01911078T patent/PT1292303E/pt unknown
- 2001-02-21 US US09/789,424 patent/US6482417B2/en not_active Expired - Fee Related
- 2001-02-21 DE DE1292303T patent/DE1292303T1/de active Pending
- 2001-02-21 DE DE60103276T patent/DE60103276T2/de not_active Expired - Fee Related
- 2001-02-21 TR TR2004/01462T patent/TR200401462T4/xx unknown
- 2001-02-21 AT AT01911078T patent/ATE266404T1/de not_active IP Right Cessation
- 2001-02-21 CN CNA018231683A patent/CN1505512A/zh active Pending
- 2001-02-21 WO PCT/US2001/005577 patent/WO2002067935A1/en not_active Ceased
-
2003
- 2003-08-20 IS IS6919A patent/IS6919A/is unknown
- 2003-08-20 NO NO20033699A patent/NO20033699L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004522780A (ja) | 2004-07-29 |
| DK1292303T3 (da) | 2004-09-06 |
| EP1292303A4 (en) | 2003-07-09 |
| IS6919A (is) | 2003-08-20 |
| DE60103276T2 (de) | 2005-06-23 |
| SK11632003A3 (sk) | 2004-04-06 |
| SI1292303T1 (en) | 2004-10-31 |
| MXPA03007908A (es) | 2004-12-06 |
| TR200401462T4 (tr) | 2004-08-23 |
| EP1292303A1 (en) | 2003-03-19 |
| CA2410802A1 (en) | 2002-09-06 |
| HUP0600143A2 (en) | 2006-10-28 |
| HRP20030762A2 (en) | 2005-08-31 |
| ES2193007T3 (es) | 2004-11-01 |
| IL157539A0 (en) | 2004-03-28 |
| US6482417B2 (en) | 2002-11-19 |
| US20020035135A1 (en) | 2002-03-21 |
| WO2002067935A1 (en) | 2002-09-06 |
| ES2193007T1 (es) | 2003-11-01 |
| DE60103276D1 (de) | 2004-06-17 |
| NO20033699L (no) | 2003-10-10 |
| EP1292303B1 (en) | 2004-05-12 |
| CN1505512A (zh) | 2004-06-16 |
| NO20033699D0 (no) | 2003-08-20 |
| ATE266404T1 (de) | 2004-05-15 |
| PT1292303E (pt) | 2004-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69732113T2 (de) | Schnelllösliche tablette enthaltend galanthaminhydrobromid | |
| RU2122413C1 (ru) | Форма фармацевтического дозирования, обеспечивающая продолжительное выделение активного ингредиента | |
| AU658171B2 (en) | Orally administerable drugs for the treatment of central dopamine deficiency conditions | |
| DE3873879T2 (de) | Nicht-sedative antihistaminica enthaltende husten-/schnupfenmittel. | |
| BR9916361A (pt) | Forma de dosagem de tabletes de liberação controlada, formulação de tablete de liberação controlada, composição granular para prensagem em uma forma de dosagem de tablete de liberação controlada, e, métodos para preparar uma composição granular, para preparar uma forma de dosagem de tabletes de liberação controlada de divalproex sódio e para tratar epilepsia | |
| US6191153B1 (en) | Use of 2-amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazole as a pharmaceutical composition having an antidepressant activity | |
| YU215090A (sr) | Formulacija u obliku pilule za kontrolisano oslobađanje | |
| JPH0753364A (ja) | 高及び低粘度のｈｐｍｃを用いた持続性の放出 | |
| HU229134B1 (en) | Process of forming a compressed solid oral dosage form comprising valsartan | |
| IS1694B (is) | Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara | |
| BE899885A (fr) | Comprimes de naproxen et de naproxen sodique a liberation controlee. | |
| ES2132170T3 (es) | Composicion de esteres de l-dopa. | |
| DE69816951D1 (de) | Zubereitung enthaltend Cefaclor oder Cephalexin mit modifizierter Freisetzungsmatrix | |
| DE1292303T1 (de) | Eine stabile pharmazeutische formulierung die torsemid modifikation ii enthält | |
| AU659114B2 (en) | Method for the manufacture of a controlled release solid unit dosage form | |
| FI89238B (fi) | Foerfarande foer framstaellning av kompressionsbelagda tabletter | |
| HU224192B1 (hu) | Tianeptin-nátriumsó nyújtott felszabadulását biztosító, szájon át beadható mátrix tabletta és eljárás előállítására | |
| CA2034519A1 (en) | Pharmaceutical compositions and dosage forms for the oral administration of calcitonin | |
| DE60306747T2 (de) | Perindopril enthaltende pharmazeutische zusammensetzung mit oraler dispersion | |
| GB2067900A (en) | Tablets containing trimethoprim, sulphamethoxazole and polyvinylpyrrolidone | |
| CA2087147A1 (en) | Method for administration of azauridine for the treatment of rheumatoid arthritis | |
| US5158776A (en) | Solid oral dosage forms of ifosfamide | |
| NZ508888A (en) | Cyclophosphamide coated tablets having no preswollen starch | |
| JPH01211527A (ja) | 更年期障害及びオステオポローシスの治療用医薬投与ユニット | |
| CA1326632C (en) | Long-active drug formulations comprising galanthamine for treatment of alzheimer's disease |